142 related articles for article (PubMed ID: 37166579)
1. Prevention of radiation-induced liver toxicity after interstitial HDR brachytherapy by pentoxifylline and ursodeoxycholic acid: patient compliance and outcome in a randomized trial.
Damm R; Wybranska J; Hass P; Walke M; Omari J; Pech M; Seidensticker R; Ricke J; Seidensticker M
J Cancer Res Clin Oncol; 2023 Sep; 149(11):9043-9049. PubMed ID: 37166579
[TBL] [Abstract][Full Text] [Related]
2. Prospective randomized trial of enoxaparin, pentoxifylline and ursodeoxycholic acid for prevention of radiation-induced liver toxicity.
Seidensticker M; Seidensticker R; Damm R; Mohnike K; Pech M; Sangro B; Hass P; Wust P; Kropf S; Gademann G; Ricke J
PLoS One; 2014; 9(11):e112731. PubMed ID: 25393877
[TBL] [Abstract][Full Text] [Related]
3. Correlation of chemokines and growth factors with radiation-induced liver injury after interstitial high dose rate (HDR) brachytherapy of liver metastases.
Damm R; Pech M; Cavalli P; Haag F; Gylstorff S; Omari J; Thormann M; Seidensticker R; Ricke J; Seidensticker M; Relja B
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2815-2826. PubMed ID: 35596772
[TBL] [Abstract][Full Text] [Related]
4. TNF-α Indicates Radiation-induced Liver Injury After Interstitial High Dose-rate Brachytherapy.
Damm R; Pech M; Haag F; Cavalli P; Gylstorff S; Omari J; Seidensticker R; Ricke J; Seidensticker M; Relja B
In Vivo; 2022; 36(5):2265-2274. PubMed ID: 36099091
[TBL] [Abstract][Full Text] [Related]
5. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
[TBL] [Abstract][Full Text] [Related]
6. Prospective evaluation of CT-guided HDR brachytherapy as a local ablative treatment for renal masses: a single-arm pilot trial.
Damm R; Streitparth T; Hass P; Seidensticker M; Heinze C; Powerski M; Wendler JJ; Liehr UB; Mohnike K; Pech M; Ricke J
Strahlenther Onkol; 2019 Nov; 195(11):982-990. PubMed ID: 31346674
[TBL] [Abstract][Full Text] [Related]
7. Does an Algorithmic Approach to Using Brachytherapy and External Beam Radiation Result in Good Function, Local Control Rates, and Low Morbidity in Patients With Extremity Soft Tissue Sarcoma?
Klein J; Ghasem A; Huntley S; Donaldson N; Keisch M; Conway S
Clin Orthop Relat Res; 2018 Mar; 476(3):634-644. PubMed ID: 29443850
[TBL] [Abstract][Full Text] [Related]
8. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
9. Comparison of liver exposure in CT-guided high-dose rate (HDR) interstitial brachytherapy versus SBRT in hepatocellular carcinoma.
Walter F; Nierer L; Rottler M; Duque AS; Weingandt H; Well J; Shpani R; Landry G; Seidensticker M; Streitparth F; Ricke J; Belka C; Corradini S
Radiat Oncol; 2021 May; 16(1):86. PubMed ID: 33957941
[TBL] [Abstract][Full Text] [Related]
10. A randomized controlled trial comparing the effects of Vitamin E, Ursodeoxycholic acid and Pentoxifylline on Egyptian non-alcoholic steatohepatitis patients.
Fouda A; Abdelaziz AE; Hussien M; Ali AA; Abdelkawy KS; Elbarbry F
Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7449-7459. PubMed ID: 34919247
[TBL] [Abstract][Full Text] [Related]
11. Salvage brachytherapy for locally-recurrent prostate cancer after radiation therapy: A comparison of efficacy and toxicity outcomes with high-dose rate and low-dose rate brachytherapy.
Henríquez López I; González-San Segundo C; Vegas JO; Gutierrez C; Hervas A; Cabeza Rodriguez MÁ; Valero Albarrán J; Rodríguez Villalba S; Álvarez Gonzalez A; Sancho Pardo G; Zapatero A; Álvaro PC
Radiother Oncol; 2019 Dec; 141():156-163. PubMed ID: 31570236
[TBL] [Abstract][Full Text] [Related]
12. American Brachytherapy Task Group Report: A pooled analysis of clinical outcomes for high-dose-rate brachytherapy for cervical cancer.
Mayadev J; Viswanathan A; Liu Y; Li CS; Albuquerque K; Damato AL; Beriwal S; Erickson B
Brachytherapy; 2017; 16(1):22-43. PubMed ID: 28109631
[TBL] [Abstract][Full Text] [Related]
13. High-dose-rate brachytherapy monotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer.
Yamazaki H; Masui K; Suzuki G; Nakamura S; Yamada K; Okihara K; Shiraishi T; Yoshida K; Kotsuma T; Tanaka E; Otani K; Yoshioka Y; Ogawa K
Radiother Oncol; 2019 Mar; 132():162-170. PubMed ID: 30416045
[TBL] [Abstract][Full Text] [Related]
14. Value of diffusion weighted MR imaging as an early surrogate parameter for evaluation of tumor response to high-dose-rate brachytherapy of colorectal liver metastases.
Wybranski C; Zeile M; Löwenthal D; Fischbach F; Pech M; Röhl FW; Gademann G; Ricke J; Dudeck O
Radiat Oncol; 2011 Apr; 6(1):43. PubMed ID: 21524305
[TBL] [Abstract][Full Text] [Related]
15. 3D-image-guided HDR-brachytherapy versus 2D HDR - brachytherapy after external beam radiotherapy for early T-stage nasopharyngeal carcinoma.
Ren Y; Zhao Q; Liu H; Huang Y; Wang Z; Cao X; Teh BS; Wen B
BMC Cancer; 2014 Nov; 14():894. PubMed ID: 25432818
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis between interstitial brachytherapy and stereotactic body irradiation for local ablation in liver malignancies.
Hass P; Mohnike K; Kropf S; Brunner TB; Walke M; Albers D; Petersen C; Damm R; Walter F; Ricke J; Powerski M; Corradini S
Brachytherapy; 2019; 18(6):823-828. PubMed ID: 31522972
[TBL] [Abstract][Full Text] [Related]
17. Interstitial high-dose-rate brachytherapy as salvage treatment for locally recurrent prostate cancer after definitive radiation therapy: Toxicity and 5-year outcome.
Jiang P; van der Horst C; Kimmig B; Zinsser F; Poppe B; Luetzen U; Juenemann KP; Dunst J; Siebert FA
Brachytherapy; 2017; 16(1):186-192. PubMed ID: 28341011
[TBL] [Abstract][Full Text] [Related]
18. Ultra-hypofractionated radiotherapy for low- and intermediate risk prostate cancer: High-dose-rate brachytherapy vs stereotactic ablative radiotherapy.
Tsang YM; Tharmalingam H; Belessiotis-Richards K; Armstrong S; Ostler P; Hughes R; Alonzi R; Hoskin PJ
Radiother Oncol; 2021 May; 158():184-190. PubMed ID: 33639192
[TBL] [Abstract][Full Text] [Related]
19. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
20. Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer.
Mohammed N; Kestin L; Ghilezan M; Krauss D; Vicini F; Brabbins D; Gustafson G; Ye H; Martinez A
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):204-12. PubMed ID: 21167653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
